<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402219</url>
  </required_header>
  <id_info>
    <org_study_id>2008A030201002</org_study_id>
    <nct_id>NCT01402219</nct_id>
  </id_info>
  <brief_title>Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients</brief_title>
  <acronym>NEIHR</acronym>
  <official_title>Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients:A Multicentre Randomized Double-Blind Trail of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN)&#xD;
      following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque&#xD;
      320) in patients with chronic kidney disease undergoing coronary angiography.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the incidence of contrast-induced nephropathy (CIN)(an absolute SCr increase 0.5&#xD;
      mg/dL from baseline) following the administration of iopamidol-370 (Iopamiro-370) and&#xD;
      iodixanol-320 (Visipaque 320) in patients with chronic kidney disease (serum creatinine level&#xD;
      more than 1.5 mg/dL for men and more than 1.3 mg/dL for women or preprocedural estimated&#xD;
      glomerular ﬁltration rate(eGFR):15-60 mL/min/1.73 m2) undergoing coronary angiography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    There were few eligible subjects from other centers.&#xD;
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>contrast-induced nephropathy</measure>
    <time_frame>48-72 h</time_frame>
    <description>Contrast-Induced Nephropathy was defined as an increase in serum creatinine of more than 0.5 mg/dl or 25% from the baseline within 48-72 h of contrast exposure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A relative increase in serum creatinine</measure>
    <time_frame>48-72 h</time_frame>
    <description>A relative increase in serum creatinine was defined as more than 25% increase in serum creatinine within 48-72 h of contrast exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A relative increase in estimated glomerular ﬁltration rate (eGFR)</measure>
    <time_frame>48-72 h</time_frame>
    <description>A relative increase in eGFR was defined as more than 25% increase in eGFR within 48-72 h of contrast exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An absolute increase in serum creatinine</measure>
    <time_frame>48-72 h</time_frame>
    <description>An absolute increase in serum creatinine within 48-72 h of contrast exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse clinical events</measure>
    <time_frame>1 month</time_frame>
    <description>Major adverse clinical events: death, requiring renal replacement therapy, 2nd myocardial infarction,target revascularization,acute heart failure, mechanical ventilation,2nd angina,tachyarrhythmia,hypotension,intra-aortic balloon pump and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse clinical events</measure>
    <time_frame>1 year</time_frame>
    <description>Major adverse clinical events: death, requiring renal replacement therapy, acute myocardial infarction,target revascularization,acute heart failure, mechanical ventilation,2nd angina,tachyarrhythmia,hypotension,intra-aortic balloon pump and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An significant increase in serum creatinine</measure>
    <time_frame>48-72 h</time_frame>
    <description>An significant increase in serum creatinine was defined as an increase in serum creatinine of more than 1.0 mg/dl from the baseline within 48-72 h of contrast exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast-Induced Acute Kidney Injury</measure>
    <time_frame>48 h</time_frame>
    <description>Contrast-Induced Acute Kidney Injury was defined as an increase in serum creatinine concentration of more than 0.3 mg/dL from the baseline value at 48 hours after administration of the contrast exposure or the need for dialysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Chronic Renal Disease</condition>
  <arm_group>
    <arm_group_label>Iopamiro-370</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Visipaque 320</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iopamidol injection 76%</intervention_name>
    <description>Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution</description>
    <arm_group_label>Iopamiro-370</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iodixanol</intervention_name>
    <description>Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution</description>
    <arm_group_label>Visipaque 320</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provides written Informed Consent and is willing to comply with protocol requirements&#xD;
&#xD;
          -  Is ≥18 years of age&#xD;
&#xD;
          -  Has a documented predose serum creatinine level of ≥1.5 mg/dL for men and ≥ 1.3 mg/dL&#xD;
             for women or predose estimated glomerular ﬁltration rate (eGFR) of &gt; 15 and ≤ 60&#xD;
             mL/min/1.73 m2, calculated via the MDRD formula from a SCr obtained within 72 hours of&#xD;
             enrollment into the study;&#xD;
&#xD;
          -  Is referred for cardiac angiography with or without PCI;&#xD;
&#xD;
          -  If at the discretion of the Investigator is receiving or will be receiving a&#xD;
             prophylactic medication for renal function, the medication is one that is permitted by&#xD;
             this protocol (N acetylcysteine, 1200 mg twice daily on the day before and on the day&#xD;
             of the cardiac angiography procedure);&#xD;
&#xD;
          -  Undergoes or is scheduled to undergo pre, peri, or post procedure hydration permitted&#xD;
             by this protocol, i.e.:&#xD;
&#xD;
          -  154 mEq/L sodium bicarbonate solution, administered intravenously at 3 mL/kg/hr for 1&#xD;
             hour before cardiac angiography, followed by an infusion of 1 mL/kg/hr during and out&#xD;
             to 6 hours after cardiac angiography, or 0.9% normal saline administered intravenously&#xD;
             at 1 mL/kg/hr for 8-12 hours before cardiac angiography, followed by an infusion of 1&#xD;
             mL/kg/hr during and out to 24 hours after cardiac angiography,for the patients with&#xD;
             left ventricular ejection fraction &lt;35% or congestive heart failure (class III in&#xD;
             accordance with the classification of the New York Heart Association (NYHA), the rate&#xD;
             of infusion decreases to half of the above ordinary rate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is a pregnant or lactating female. Exclude the possibility of pregnancy: by laboratory&#xD;
             testing on-site at the institution (measurement of serum or urine βHCG) within 24&#xD;
             hours prior to the start of investigational product administration by history (e.g.,&#xD;
             tubal ligation or hysterectomy, post menopausal with a minimum 1 year without menses)&#xD;
&#xD;
          -  Has a history of hypersensitivity to iodine-containing compounds;&#xD;
&#xD;
          -  Has unstable renal function (i.e., acute worsening of renal function, as determined by&#xD;
             the Investigator, that has been observed in the 7 days prior to enrollment) and/or is&#xD;
             in acute renal failure;&#xD;
&#xD;
          -  Has end-stage renal disease (i.e., eGFR &lt;15 mL/min/1.73 m2)&#xD;
&#xD;
          -  Has severe congestive heart failure (class IV in accordance with the classification of&#xD;
             the New York Heart Association (NYHA) ;&#xD;
&#xD;
          -  Has uncontrolled diabetes, as determined by the Investigator;&#xD;
&#xD;
          -  Has received an iodinated contrast agent within 7 days prior to the administration of&#xD;
             the study agent or is scheduled to receive an iodinated contrast agent within 72 hours&#xD;
             after administration of the study agent; intake of nephrotoxic drugs within the&#xD;
             previous seven days Prior to, during or post the cardiac angiography, is receiving or&#xD;
             will be receiving a prophylactic medication to prevent acute kidney injury that is not&#xD;
             permitted by this protocol (e.g., theophylline, fenoldopam, etc.);&#xD;
&#xD;
          -  Is planned to undergo major surgery (e.g. CABG, valve surgery, etc.) within 48-72&#xD;
             hours after contrast administration;&#xD;
&#xD;
          -  Is planned to receive an intravenous diuretic or mannitol as prophylaxis to prevent&#xD;
             acute renal injury (Note: chronic administration is allowed);&#xD;
&#xD;
          -  Is hemodynamically unstable within 48 hours pre-contrast administration defined as a&#xD;
             systolic blood pressure &lt; 90 mmHg or requires pressor or intra-aortic balloon support&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiyan Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>chen-jiyan@163.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yingling Zhou, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong Cardiovascular Institute,Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>liuyongyisheng@126.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangdong Cardiovascular Institute,Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Jiyan Chen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>contrast-induced nephropathy</keyword>
  <keyword>contrast medium</keyword>
  <keyword>creatinine clearance</keyword>
  <keyword>coronary angiography</keyword>
  <keyword>chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

